Source: Υπουργείο Υγείας (CY) Revision Year: 2017 Publisher: MEDOCHEMIE LTD, 1-10 Constantinoupoleos street, 3011 Limassol, Cyprus
Medovent is indicated as secretolytic, for the treatment of acute bronchial disorders or acute episodes of chronic bronchopneumopathy or other chronic bronchopulmonary disorders associated with abnormal mucous secretion and impaired mucus transport.
Medovent 30mg tablets is reserved for treatment in adults.
The recommended dose is 1 tablet three times a day.
The therapeutic effect can be enhanced by administering 2 tablets of Medovent (60 mg ambroxol hydrochloride) per day given orally in two divided doses.
If your symptoms have not improved after treatment with Medovent for acute respiratory illness, you should consult your doctor.
The tablets must be swallowed with sufficient fluid.
Medovent can be taken with or without food.
There are no described overdosing effects in man. Based on reports of accidental overdoses or/and errors in administration, observed symptoms are similar to known side effects at recommended doses and if they occur, symptomatic treatment should be administrated.
5 years.
Store below 25°C, in the original package, in order to protect from light.
Polyvinylchloride film-aluminium foil blisters, with a patient information leaflet in a card carton. Packs containing 20, 30, 50 and 60 tablets are available.
Polyvinylchloride securitainers with a tamper evident closure containing 250, 500, or 1000 tablets are also available.
Not all pack sizes may be marketed.
No special requirements for disposal.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
